Patient-Based Therapeutics

AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.

get to know us

Patient Focused

rp3.jpgrp1.jpgrp2.jpg

rp4.jpgThe main reason drugs fail in clinical trials is due to an over reliance on animal models, which leads to a poor understanding of the real human mechanisms driving disease. AcuraStem are leaders and inventors in the generation of individual patient models that accurately recapitulate neurodegenerative disease processes. This, what we call our patient-based approach, leads to more effective treatments, and treatments that can work broadly for patients, not limited to rare, genetically defined subtypes. 


learn about our work

Neurodegenerative Disease Areas

Latest News

September 9, 2024

AcuraStem CEO Sam Alworth Champions RNA Therapeutics at RNA Leaders USA Congress

At the RNA Leaders USA Congress, held September 4-5, 2024, at the San Diego Convention Center, AcuraStem CEO Sam Alworth delivered a key presentation titled 'Accelerating the Development of More Effective Treatments for ALS & FTD Using the iNeuroRx® Technology Platform.'

» Read more
September 3, 2024

AcuraStem Secures $4 Million in Grant Funding from CIRM to Advance UNC13A Program for ALS and FTD

AcuraStem, a patient-based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that it has successfully secured $4 million in grant funding from the California Institute for Regenerative Medicine (CIRM) as part of CIRM's Therapeutic Translational Research Projects program, which accelerates the preclinical development of innovative therapies.

» Read more
August 26, 2024

AcuraStem Appoints Dr. Rafael Renteria as Principal Scientist, hiPSC Platform

AcuraStem, a patient-based biotechnology company pioneering the development of treatments for neurodegenerative diseases, today announced the appointment of Dr. Rafael Renteria as Principal Scientist, hiPSC Platform.

» Read more

Keep Up to Date with AcuraStem